Dr. Douglas Faller is a Boston-based physician/scientist with over 15 years of pharmaceutical and biotech experience involving discovery, pre-clinical and clinical development of small molecules for several therapeutic areas, specializing in oncology and hematology, plus over 25 years of academic clinical and laboratory research experience in the fields of drug discovery and development, oncology and hematology, cell and molecular biology, management of professionals, including the programmatic organization of large groups of scientists, and development of research and drug development programs.
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
- Harvard University, MD
- Massachusetts Institute of Technology, PhD
- Massachusetts Institute of Technology, BS
- Published on 3/31/2020
Moos WH, Faller DV, Glavas IP, Harpp DN, Kanara I, Mavrakis AN, Pernokas J, Pernokas M, Pinkert CA, Powers WR, Sampani K, Steliou K, Vavvas DG, Zamboni RJ, Kodukula K, Chen X. Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs. Biores Open Access. 2020; 9(1):94-105. PMID: 32257625.
- Published on 9/4/2019
Faessel HM, Mould DR, Zhou X, Faller DV, Sedarati F, Venkatakrishnan K. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. Br J Clin Pharmacol. 2019 Nov; 85(11):2568-2579. PMID: 31355467.
- Published on 6/19/2019
Bell JA, Galaznik A, Pompilus F, Strzok S, Bejar R, Scipione F, Fram RJ, Faller DV, Cano S, Marquis P. A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Patient Rep Outcomes. 2019 Jun 19; 3(1):35. PMID: 31218454.
- Published on 6/1/2019
Bell JA, Galaznik A, Blazer M, Shih HC, Farrelly E, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV. Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States. Pharmacoecon Open. 2019 Jun; 3(2):237-245. PMID: 30324565.
- Published on 5/17/2019
Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. Br J Clin Pharmacol. 2019 07; 85(7):1464-1473. PMID: 30845347.
- Published on 1/24/2019
Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota VK. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent. Leuk Res. 2019 03; 78:45-51. PMID: 30716655.
- Published on 12/21/2018
Faller DV. Response to "Selective PKCd Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms". ACS Chem Biol. 2019 01 18; 14(1):131. PMID: 30525445.
- Published on 7/1/2018
Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K. A New Approach to Treating Neurodegenerative Otologic Disorders. Biores Open Access. 2018; 7(1):107-115. PMID: 30069423.
- Published on 6/22/2018
Bell JA, Galaznik A, Blazer M, Farrelly E, Ogbonnaya A, Raju A, Eaddy M, Fram RJ, Faller DV. Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. Leuk Lymphoma. 2019 01; 60(1):49-59. PMID: 29932781.
- Published on 6/18/2018
Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota V. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018 08; 71:27-33. PMID: 29944984.
View 278 more publications: View full profile at BUMC